as 11-12-2024 4:00pm EST
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Founded: | 2012 | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 7.2B | IPO Year: | 2015 |
Target Price: | $109.80 | AVG Volume (30 days): | 6.1M |
Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.93 | EPS Growth: | N/A |
52 Week Low/High: | $10.34 - $99.41 | Next Earning Date: | 10-23-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
MACARTNEY LAWSON | VKTX | Director | Nov 8 '24 | Sell | $68.67 | 2,000 | $137,333.40 | 47,965 | |
SINGLETON J MATTHEW | VKTX | Director | Oct 25 '24 | Sell | $79.50 | 16,000 | $1,272,000.00 | 9,500 | |
Rouan Sarah Kathryn | VKTX | Director | Oct 25 '24 | Sell | $80.89 | 11,000 | $889,790.00 | 0 | |
Lian Brian | VKTX | President & CEO | Sep 20 '24 | Sell | $71.19 | 216,130 | $15,308,552.90 | 2,304,927 | |
SINGLETON J MATTHEW | VKTX | Director | Sep 20 '24 | Sell | $69.50 | 10,300 | $715,850.00 | 9,500 | |
SINGLETON J MATTHEW | VKTX | Director | Aug 21 '24 | Sell | $69.72 | 5,700 | $397,430.22 | 9,500 | |
Lian Brian | VKTX | President & CEO | Aug 19 '24 | Sell | $66.27 | 112,870 | $7,426,507.68 | 2,304,927 | |
SINGLETON J MATTHEW | VKTX | Director | Aug 19 '24 | Sell | $62.52 | 16,000 | $995,453.24 | 9,500 |
VKTX Breaking Stock News: Dive into VKTX Ticker-Specific Updates for Smart Investing
PR Newswire
8 hours ago
Motley Fool
3 days ago
Motley Fool
5 days ago
Motley Fool
6 days ago
GuruFocus.com
7 days ago
Clinical Trials Arena
8 days ago
Motley Fool
8 days ago
Motley Fool
8 days ago
The information presented on this page, "VKTX Viking Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.